Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Study: Options After Anti-TNF Failure In RA

This article was originally published in Scrip

Executive Summary

Doctors participating in a new, small study reviewed a Slovenian patient registry in an attempt to answer a long-unanswered question for rheumatoid arthritis patients: After failing to respond or following a short-lived response to tumor necrosis factor (TNF) inhibitors, such as the AbbVie Inc. blockbuster Humira (adalimumab) or Amgen Inc.'s Enbrel (etanercept), is second-line treatment with another anti-TNF therapy the best option or should other mechanisms of action be considered?



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts